Skip to main content
SpringerLink
Log in

The management of patients with enteric hyperoxaluria

  • Invited Review
  • Published:
Urolithiasis Aims and scope Submit manuscript

Abstract

Enteric hyperoxaluria is a common occurrence in the setting of fat malabsorption, usually due to intestinal resection or intestinal bypass surgery. Enhanced intestinal absorption of dietary oxalate leads to elevated renal oxalate excretion, frequently in excess of 100 mg/d (1.14 mmol/d). Patients are at increased risk of urolithiasis and loss of kidney function from oxalate nephropathy. Fat malabsorption causes increased binding of diet calcium by free fatty acids, reducing the calcium available to precipitate diet oxalate. Delivery of unabsorbed bile salts and fatty acids to the colon increases colonic permeability, the site of oxalate hyper-absorption in enteric hyperoxaluria. The combination of soluble oxalate in the intestinal lumen and increased permeability of the colonic mucosa leads to hyperoxaluria. Dietary therapy consists of limiting oxalate and fat intake. The primary medical intervention is the use of oral oxalate binding agents such as calcium salts to reduce free intestinal oxalate levels. Bile acid sequestrants can be useful in patients with ileal resection and bile acid malabsorption. Oxalate degrading bacteria provided as probiotics are being investigated but as of yet, no definite benefit has been shown with currently available preparations. The current state of medical therapy and potential future directions will be summarized in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

BPD:

Biliopancreatic diversion

EH:

Enteric hyperoxaluria

JIB:

Jejunoileal bypass

ODB:

Oxalate degrading bacteria

RYGB:

Roux-en-Y gastric bypass

References

  1. Mole DR, Tomson CR, Mortensen N, Winearls CG (2001) Renal complications of jejuno-ileal bypass for obesity. QJM 94:69–77

    Article  CAS  PubMed  Google Scholar 

  2. Asplin JR, Coe FL (2007) Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 177:565–569

    Article  PubMed  Google Scholar 

  3. Nelson WK, Houghton SG, Milliner DS, Lieske JC, Sarr MG (2005) Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 1:481–485

    Article  PubMed  Google Scholar 

  4. Nasr SH, D’Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, Markowitz GS (2008) Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 3:1676–1683

    Article  PubMed Central  PubMed  Google Scholar 

  5. Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J (2011) Trends in use of bariatric surgery; 2003–2008. J Am Coll Surg 213:261–266

    Article  PubMed  Google Scholar 

  6. Holmes RP, Goodman HO, Assimos DG (2001) Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 59:270–276

    Article  CAS  PubMed  Google Scholar 

  7. Brinkley L, McGuire J, Gregory J, Pak CY (1981) Bioavailability of oxalate in foods. Urology 17:534–538

    Article  CAS  PubMed  Google Scholar 

  8. Hess B, Jost C, Zipperle L, Takkinen R, Jaeger P (1998) High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 13:2241–2247

    Article  CAS  PubMed  Google Scholar 

  9. Liebman M, Chai W (1997) Effect of dietary calcium on urinary oxalate excretion after oxalate loads. Am J Clin Nutr 65:1453–1459

    CAS  PubMed  Google Scholar 

  10. Chen Z, Ye Z, Zeng L, Yang W (2003) Clinical investigation on gastric oxalate absorption. Chin Med J (Engl) 116:1749–1751

    CAS  Google Scholar 

  11. Smith LH, Fromm H, Hofmann AF (1972) Acquired hyperoxaluria, nephrolithiasis, and intestinal disease. Description of a syndrome. N Engl J Med 286:1371–1375

    Article  CAS  PubMed  Google Scholar 

  12. Dowling RH, Rose GA, Sutor DJ (1971) Hyperoxaluria and renal calculi in ileal disease. Lancet 1:1103–1106

    Article  CAS  PubMed  Google Scholar 

  13. Barilla DE, Notz C, Kennedy D, Pak CY (1978) Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias. Effect of calcium and magnesium. Am J Med 64:579–585

    Article  CAS  PubMed  Google Scholar 

  14. Chadwick VS, Modha K, Dowling RH (1973) Mechanism for hyperoxaluria in patients with ileal dysfunction. N Engl J Med 289:172–176

    Article  CAS  PubMed  Google Scholar 

  15. Earnest DL, Johnson G, Williams HE, Admirand WH (1974) Hyperoxaluria in patients with ileal resection: an abnormality in dietary oxalate absorption. Gastroenterology 66:1114–1122

    CAS  PubMed  Google Scholar 

  16. Froeder L, Arasaki CH, Malheiros CA, Baxmann AC, Heilberg IP (2012) Response to dietary oxalate after bariatric surgery. Clin J Am Soc Nephrol 7:2033–2040

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Dobbins JW, Binder HJ (1977) Importance of the colon in enteric hyperoxaluria. N Engl J Med 296:298–301

    Article  CAS  PubMed  Google Scholar 

  18. Modigliani R, Labayle D, Aymes C, Denvil R (1978) Evidence for excessive absorption of oxalate by the colon in enteric hyperoxaluria. Scand J Gastroenterol 13:187–192

    Article  CAS  PubMed  Google Scholar 

  19. Earnest DL, Williams HE, Admirand WH (1975) A physicochemical basis for treatment of enteric hyperoxaluria. Trans Assoc Am Physicians 88:224–234

    CAS  PubMed  Google Scholar 

  20. Dobbins JW, Binder HJ (1976) Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology 70:1096–1100

    CAS  PubMed  Google Scholar 

  21. Parks JH, Worcester EM, O’Connor RC, Coe FL (2003) Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 63:255–265

    Article  PubMed  Google Scholar 

  22. Maalouf NM, Tondapu P, Guth ES, Livingston EH, Sakhaee K (2010) Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery. J Urol 183:1026–1030

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hamm LL (1990) Renal handling of citrate. Kidney Int 38:728–735

    Article  CAS  PubMed  Google Scholar 

  24. Puzziferri N, Blankenship J, Wolfe BM (2006) Surgical treatment of obesity. Endocrine 29:11–19

    Article  CAS  PubMed  Google Scholar 

  25. Gregory JG, Park KY, Schoenberg HW (1977) Oxalate stone disease after intestinal resection. J Urol 117:631–634

    CAS  PubMed  Google Scholar 

  26. Pang R, Linnes MP, O’Connor HM, Li X, Bergstralh E, Lieske JC (2012) Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology 80:250–254

    Article  PubMed Central  PubMed  Google Scholar 

  27. Andersson H, Jagenburg R (1974) Fat-reduced diet in the treatment of hyperoxaluria in patients with ileopathy. Gut 15:360–366

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Nordenvall B, Backman L, Burman P, Larsson L, Tiselius HG (1983) Low-oxalate, low-fat dietary regimen in hyperoxaluria following jejunoileal bypass. Acta Chir Scand 149:89–91

    CAS  PubMed  Google Scholar 

  29. Caspary WF, Tonissen J, Lankisch PG (1977) ‘Enteral’ hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man. Acta Hepatogastroenterol (Stuttg) 24:193–200

    CAS  Google Scholar 

  30. Hylander E, Jarnum S, Nielsen K (1980) Calcium treatment of enteric hyperoxaluria after jejunoileal bypass for morbid obesity. Scand J Gastroenterol 15:349–352

    Article  CAS  PubMed  Google Scholar 

  31. Stauffer JQ (1977) Hyperoxaluria and intestinal disease. The role of steatorrhea and dietary calcium in regulating intestinal oxalate absorption. Am J Dig Dis 22:921–928

    Article  CAS  PubMed  Google Scholar 

  32. Walker VR, Sutton RA (1994) Calcium supplementation for enteric hyperoxaluria secondary to intestinal bypass. In: Ryall R, Bais R, Marshall VR, Rofe AM, Smith LH, Walker VR (eds) Urolithiasis 2. Plenum, New York, pp 557–561

    Chapter  Google Scholar 

  33. Rodgers AL, Allie-Hamdulay S, Jackson GE, Sutton RA (2014) Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols. J Endourol 28:985–994

    Article  PubMed  Google Scholar 

  34. Tondapu P, Provost D, Adams-Huet B, Sims T, Chang C, Sakhaee K (2009) Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg 19:1256–1261

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Sakhaee K, Griffith C, Pak CY (2012) Biochemical control of bone loss and stone-forming propensity by potassium-calcium citrate after bariatric surgery. Surg Obes Relat Dis 8:67–72

    Article  PubMed  Google Scholar 

  36. Zimmermann DJ, Voss S, Von Unruh GE, Hesse A (2005) Importance of magnesium in absorption and excretion of oxalate. Urol Int 74:262–267

    Article  CAS  PubMed  Google Scholar 

  37. Liebman M, Costa G (2000) Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 163:1565–1569

    Article  CAS  PubMed  Google Scholar 

  38. Nordenvall B, Backman L, Larsson L, Tiselius HG (1983) Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass. Acta Chir Scand 149:93–98

    CAS  PubMed  Google Scholar 

  39. Lieske JC, Regnier C, Dillon JJ (2008) Use of sevelamer hydrochloride as an oxalate binder. J Urol 179:1407–1410

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR (2002) Bile acid binding to sevelamer HCl. Kidney Int 62:611–619

    Article  CAS  PubMed  Google Scholar 

  41. Robijn S, Vervaet BA, Hoppe B, D’Haese PC, Verhulst A (2013) Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 189:1960–1966

    Article  CAS  PubMed  Google Scholar 

  42. Binder HJ (1974) Intestinal oxalate absorption. Gastroenterology 67:441–446

    CAS  PubMed  Google Scholar 

  43. Stauffer JQ, Humphreys MH, Weir GJ (1973) Acquired hyperoxaluria with regional enteritis after ileal resection. Role of dietary oxalate. Ann Intern Med 79:383–391

    Article  CAS  PubMed  Google Scholar 

  44. Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141:1–7

    Article  CAS  PubMed  Google Scholar 

  45. Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, Cave DR (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19:1197–1203

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Mittal RD, Kumar R, Mittal B, Prasad R, Bhandari M (2003) Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract 12:208–213

    Article  CAS  PubMed  Google Scholar 

  47. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW (2006) Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 69:691–698

    Article  CAS  PubMed  Google Scholar 

  48. Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG (2011) Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol 186:135–139

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Kumar R, Ghoshal UC, Singh G, Mittal RD (2004) Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastroenterol Hepatol 19:1403–1409

    Article  PubMed  Google Scholar 

  50. Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV (1986) Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 116:455–460

    CAS  PubMed  Google Scholar 

  51. Duffey BG, Miyaoka R, Holmes R, Assimos D, Hinck B, Korman E, Kieley F, Ikramuddin S, Kellogg T, Moeding A, Monga M (2011) Oxalobacter colonization in the morbidly obese and correlation with urinary stone risk. Urology 78:531–534

    Article  PubMed  Google Scholar 

  52. Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C (2001) Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 60:1097–1105

    Article  CAS  PubMed  Google Scholar 

  53. Lieske JC, Tremaine WJ, De SC, O’Connor HM, Li X, Bergstralh EJ, Goldfarb DS (2010) Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 78:1178–1185

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Goldfarb DS, Modersitzki F, Asplin JR (2007) A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2:745–749

    Article  PubMed  Google Scholar 

  55. Lieske JC, Goldfarb DS, De Simone C, Regnier C (2005) Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 68:1244–1249

    Article  CAS  PubMed  Google Scholar 

  56. McDonald GB, Earnest DL, Admirand WH (1977) Hyperoxaluria correlates with fat malabsorption in patients with sprue. Gut 18:561–566

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Singh A, Sarkar SR, Gaber LW, Perazella MA (2007) Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 49:153–157

    Article  CAS  PubMed  Google Scholar 

  58. Dhar NB, Grundfest S, Jones JS, Streem SB (2005) Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation. J Urol 174:1844–1846

    Article  PubMed  Google Scholar 

  59. Economou TP, Cullen JJ, Mason EE, Scott DH, Doherty C, Maher JW (1995) Reversal of small intestinal bypass operations and concomitant vertical banded gastroplasty: long-term outcome. J Am Coll Surg 181:160–164

    CAS  PubMed  Google Scholar 

  60. Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, Magnuson T, Schweitzer M, Matlaga BR (2010) The effect of restrictive bariatric surgery on urinary stone risk factors. Urology 76:826–829

    Article  PubMed  Google Scholar 

  61. Semins MJ, Matlaga BR, Shore AD, Steele K, Magnuson T, Johns R, Makary MA (2009) The effect of gastric banding on kidney stone disease. Urology 74:746–749

    Article  PubMed Central  PubMed  Google Scholar 

  62. Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG (2013) Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145:996–1006

    Article  PubMed  Google Scholar 

  63. Ceulemans LJ, Nijs Y, Nuytens F, De HG, Claes K, Bammens B, Naesens M, Evenepoel P, Kuypers D, Vanrenterghem Y, Monbaliu D, Pirenne J (2013) Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome. Am J Transplant 13:1910–1914

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Litholink® Corporation, Laboratory Corporation of America® Holdings, 2250 W Campbell Park Dr., Chicago, IL, 60612, USA

    John R. Asplin

Authors
  1. John R. Asplin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R. Asplin.

Ethics declarations

No funding was provided in support of this work.

Conflict of interest

John Asplin is an employee of Litholink/LabCorp, a company that provides laboratory testing for patients with kidney stones.

Ethical approval

This article does not contain any studies with animals performed by any of the authors.

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asplin, J.R. The management of patients with enteric hyperoxaluria. Urolithiasis 44, 33–43 (2016). https://doi.org/10.1007/s00240-015-0846-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00240-015-0846-5

Keywords

Search

Navigation